DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-220/S-027

Bayer HealthCare Pharmaceuticals, Inc.
Attention: Kevin N. Hibbert, MD, MPH
Director, Global Regulatory Affairs
P.O. Box 1000
Montville, NJ 07045-1000

Dear Dr. Hibbert:

Please refer to your supplemental new drug application dated February 27, 2007, received March 1, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Ultravist® (brand of iopromide) Injection.

We acknowledge receipt of your submissions dated February 2, August 28, 29 and 30, 2007.

This "Changes Being Effected" supplemental new drug application amends the **DRUG HANDLING** section of the package insert with additional text regarding visual inspections of containers before use. The proposed new statements would be added to the 6th (last) paragraph of the **DRUG HANDLING** section, which will now read:

> **DRUG HANDLING:**
> As with all contrast agents, because of the potential for chemical incompatibility, ULTRAVIST Injection should not be mixed with, *or injected in, intravenous administration lines containing other drugs, solutions or total nutritional admixtures.*
>
> Sterile technique must be used in all vascular injections involving contrast agents.
>
> Intravascularly administered iodinated contrast agents should be at or close to body temperature when injected.
>
> If nondisposable equipment is used, scrupulous care should be taken to prevent residual contamination with traces of cleansing agents.
>
> Withdrawal of contrast agents from their containers should be accomplished under strict aseptic condition.
>
> Contrast agents should be visually inspected prior to use and must not be used if discolored, if particulate matter (including crystals) is present, or if containers are defective. As Ultravist is a highly concentrated solution, crystallization (milky-cloudy appearance and/or sediment at bottom, or floating crystals) may occur.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert) submitted August 30, 2007.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 20-220/S-027**." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Rene Tyson, Regulatory Project Manager, at (301) 796-1476.

Sincerely,

{See appended electronic signature page}

Rafel Dwaine Rieves, M.D.
Acting Director
Division of Medical Imaging and Hematology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Rafel Rieves

8/31/2007 02:40:21 PM